Cell-derived Microparticles Circulate in Healthy Humans and Support Low Grade Thrombin Generation

René J. Berckmans; Rienk Nieuwland; Anita N. Böing; Fred P. H. T. M. Romijn; C. Erik Hack; Augueste Sturk

doi:10.1055/s-0037-1615646

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2001; 85(04): 639-649
DOI: 10.1055/s-0037-1615646

Review Articles

Schattauer GmbH

Cell-derived Microparticles Circulate in Healthy Humans and Support Low Grade Thrombin Generation

Authors

René J. Berckmans

¹Department of Clinical Chemistry, Leiden University Medical Center, Leiden
Rienk Nieuwland

¹Department of Clinical Chemistry, Leiden University Medical Center, Leiden
Anita N. Böing

¹Department of Clinical Chemistry, Leiden University Medical Center, Leiden
Fred P. H. T. M. Romijn

¹Department of Clinical Chemistry, Leiden University Medical Center, Leiden
C. Erik Hack

²Central Laboratory of the Netherlands Red Cross Bloodtransfusion Service, Sanquin Blood Supply Foundation and University Hospital Vrije Universiteit, Amsterdam, The Netherlands
Augueste Sturk

¹Department of Clinical Chemistry, Leiden University Medical Center, Leiden

Abstract

Summary

We determined the numbers, cellular origin and thrombin-generating properties of microparticles in healthy individuals (n = 15). Micro-particles, isolated from fresh blood samples and identified by flow cytometry, originated from platelets [23710⁶/L (median; range 116-565)], erythrocytes (2810⁶/L; 13-46), granulocytes (4610⁶/L; 16-94) and endothelial cells (6410⁶/L; 16-136). They bound annexin V, indicating surface exposure of phosphatidylserine, and supported coagulation in vitro. Interestingly, coagulation occurred via tissue factor (TF)-independent pathways, because antibodies against TF or factor (F)VII were ineffective. In contrast, in our in vitro experiments coagulation was partially inhibited by antibodies against FXII (12%, p = 0.006), FXI (36%, p <0.001), FIX (28%, p <0.001) or FVIII (32%, p <0.001). Both the number of annexin V-positive microparticles present in plasma and the thrombin-generating capacity inversely correlated to the plasma concentrations of thrombin-antithrombin complex (r = -0.49, p = 0.072 and r = -0.77, p = 0.001, respectively), but did not correlate to prothrombin fragment F₁₊₂ (r = -0.002, p = 0.99). The inverse correlations between the number of microparticles and their thrombin-forming capacity and the levels of thrombin-antithrombin complex in plasma may indicate that microparticles present in the circulation of healthy individuals have an anticoagulant function by promoting the generation of low amounts of thrombin that activate protein C. We conclude that microparticles in blood from healthy individuals support thrombin generation via TF- and FVII-independent pathways, and which may have an anticoagulant function.

Keywords

Microparticles - coagulation - thrombin generation - flow cytometry - tissue factor

Full Text

References

References
1 Lämmle B, Wuillemin WA, Huber I, Krauskopf M, Zürcher C, Pflugshaupt R, Furman MI. Thromboembolism and bleeding tendency in congenital factor XII deficiency: a study on 74 subjects from 14 Swiss families. Thromb Haemost 1991; 65: 117-21.
2 von Känel R, Wuillemin WA, Furlan M, Lämmle B. Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coag Fibrinol 1992; 3: 555-61.
3 Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood 1990; 76: 731-6.
4 Gailani D, Broze Jr GJ. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-12.
5 von dem Borne PAKr, Koppelman SJ, Bouma BN, Meijers JCM. Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen. Thromb Haemost 1994; 72: 397-402.
6 von dem Borne PAKr, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 3035-42.
7 ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-12.
8 Taylor Jr FB. Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon. Haemostasis 1996; 26 (Suppl. 01) 83-91.
9 Pixley RA, De La Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor Jr FB, Colman RW. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91: 61-8.
10 Taylor Jr FB, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, Blick K, Edgington TS. Lethal E coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-34.
11 Wagenvoord RJ, Hendrix JJ, Kai H, Hemker HC. A chromogenic test to determine the procoagulant phospholipids in platelet-rich plasma and whole blood. Thromb Haemost 1994; 72: 582-7.
12 Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ, Jansen PGM, ten Have K, Eijsman L, Hack CE, Sturk A. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997; 96: 3534-41.
13 Nieuwland R, Berckmans RJ, McGregor S, B^ing AN, Romijn FPHTM, Westendorp RGJ, Hack CE, Sturk A. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95: 930-5.
14 Bauer KA, Kass BL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of factor X activation in humans. Blood 1989; 74: 2007-15.
15 Bauer KA, Mannucci PM, Gringeri A, Tradati FC, Barzegar S, Kass BL, ten Cate H, Kestin AS, Brettler DB, Rosenberg RD. Factor IXa-factor VIIIa cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. Blood 1992; 79: 2039-47.
16 Takahashi H, Satoh N, Wada K, Takakuwa E, Sekim Y, Shibata A. Tissue factor in plasma of patients with disseminated intravascular coagulation. Am J Hematol 1994; 46: 333-7.
17 Giesen PLA, Rauch U, Bohrmann B, Kling D, Roqué M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
18 Wada H, Wakita Y, Shiku H. Tissue factor expression in endothelial cells in health and disease. Blood Coag Fibrinol 1995; 6 (Suppl. 01) S26-S31.
19 Østerud B.. Tissue factor expression by monocytes: regulation and patho-physiological roles. Blood Coag Fibrinol 1998; 9 (Suppl. 01) S9-S14.
20 Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Eschwege V, Hedman H, Freyssinet JM. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immuno 1994; 153: 3245-55.
21 Kagawa H, Komiyama Y, Nakamura S, Miyaka T, Miyazaki Y. Expression of functional tissue factor on small vesicles of lipopolysaccharide-stimulated human vascular endothelial cells. Thromb Res 1998; 91: 297-304.
22 Brunner J, Skrabal P, Hauser H. Single bilayer vesicles prepared without sonication physico-chemical properties. Biochim Biophys Acta 1976; 455: 322-31.
23 Dors DM, Nuijens JH, Huijbregts CCM, Hack CE. A novel sensitive assay for functional factor XII based on the generation of kallikrein-C1-inhibitor complexes in factor XII-deficient plasma by glass-bound factor XII. Thromb Haemost 1992; 67: 644-8.
24 Siljander P, Carpen O, Lassila R. Platelet-derived microparticles associate with fibrin during thrombosis. Blood 1996; 87: 4651-63.
25 Beguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 1989; 61: 25-9.
26 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly purified IX concentrate. Br J Haematol 1991; 79: 606-11.
27 Santucci RA, Ehrlich J, Labriola J, Wilson M, Kao KJ, Kickler TS, Spillert C, Mackman N. Measurement of tissue factor activity in whole blood. Thromb Haemost 2000; 83: 445-54.
28 Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Eng J. Med 2000; 342: 696-701.
29 Clark DA, Chaouat G, Arck PC, Mittruecker HW, Levy GA. Cytokine-dependent abortion in CBADBA/2 mice is mediated by the procoagulant fgl2 prothrombinase [correction of prothombinase] [published erratum appears in J Immunol 1999 Mar 1; 162 (5): 3105]. J Immunol 1998; 160: 545-9.
30 Altieri DC, Edgington TS. The saturable high affinity association of factor X to ADP-stimulated monocytes defines a novel function of the Mac-1 receptor. J Biol Chem 1988; 263: 7007-15.
31 Combes V, Simon A-C, Grau G-E, Arnoux D, Camoin L, Sabatier F, Mutin M, Sanmarco M, Sampol J, Dignat-George F. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104: 93-102.
32 Gilbert GE, Sims PJ, Wiedmer T, Furie B, Furie BC, Shattil SJ. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem 1991; 266: 17261-8.
33 Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205-12.
34 Holme PA, Brosstad F, Solum NO. Platelet-derived microvesicles and activated platelets express factor Xa activity. Blood Coag Fibrinol 1995; 6: 302-10.
35 London F, Ahmad SS, Walsh PN. Annexin V inhibition of factor IXa-catalyzed factor X activation on human platelets and on negatively-charged phospholipid vesicles. Biochemistry 1996; 35: 16886-97.
36 Hsu TC, Shore SK, Seshsmma T, Bagasra O, Walsh PN. Molecular cloning of platelet factor XI, an alternative splicing product of the plasma factor XI gene. J Biol Chem 1998; 273: 13787-93.
37 Hu C, Baglia FA, Mills DCB, Konkle BA, Walsh PN. Tissue-specific expression of functional platelet factor XI is independent of plasma factor XI expression. Blood 1998; 91: 3800-7.
38 Wun T, Paglieroni T, Holland P. Prolonged circulation of activated platelets following plasmapheresis. J Clin Apheresis 1994; 91: 10-6.
39 Katopodis JN, Kolodny L, Jy W, Horstman LL, De Marchena EJ, Tao JG, Haynes DH, Ahn YS. Platelet microparticles and calcium homeostasis in acute coronary ischemias. Am J Hematol 1997; 54: 95-101.
40 Nomura S, Komiyama Y, Miyake T, Miyazaki Y, Kido H, Suzuki M, Kagawa H, Yanabu M, Takahashi H, Fukuhara S. Amyloid- protein precursor-rich platelet microparticles in thrombotic disease. Thromb Haemost 1994; 72: 519-22.
41 Nomura S, Shouzu A, Omoto S, Hayakawa T, Kagawa H, Nishikawa M, Inada M, Fujimura Y, Ikeda Y, Fukuhara S. Effect of cilostazol on soluble adhesion moleculaes and platelet-derived microparticles in patients with diabetes. Thromb Haemost 1998; 80: 388-92.
42 Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JAI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-9.
43 Warkentin TE. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transf Med Rev 1996; 10: 249-58.
44 Lee YJ, Jy W, Horstman LL, Janania J, Reyes Y, Kelley RE, Ahn YS. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res 1993; 72: 295-304.
45 Nomura S, Shouzu A, Nishikawa M, Kokawa T, Yasunaga K. Significance of platelet-derived microparticles in uremia. Nephron 1993; 63: 485.
46 Jy W, Horstman LL, Arce M, Ahn YS. Platelet microparticles in ITP. J Lab Clin Med 1992; 119: 334-5.
47 Kelton JG, Moore JC, Warkentin TE, Hayward CP. Isolation and characterization of cysteine proteinase in thrombotic thrombocytopenic purpura. Br J Haematol 1996; 93: 421-6.
48 Ahmad SS, Rawaia-Sheikh R, Walsh PN. Platelet receptor-mediated factor X activation by factor IXa. J Clin Invest 1989; 84: 824-8.
49 Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Anti-thrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993; 92: 2003-12.
50 Tans G, Rosing J, Christella M, Thomassen LGD, Reeb MJ, Zwaal RFA, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77: 2641-8.